AdultHip Abstracts PDF
AdultHip Abstracts PDF
AdultHip Abstracts PDF
PAPERS this study was to determine the rate of DVT and PE after total knee
arthroplasty (TKA) and total hip arthroplasty (THA) in patients
with a diagnosis of varicose veins who have or have not had previous
PAPER NO. 31 varicose vein (VV) surgery, in an attempt to determine if prior VV
diagnosis or surgery alters the risk of DVT or PE after arthroplasty.
Is Inferior Vena Cava Filter Effective at Preventing METHODS: Data on 57,364 patients who had total hip
Pulmonary Embolism? arthroplasty (THA) and 51,859 patients who had total knee
Benjamin Zmistowski, BS, Philadelphia, PA arthroplasty (TKA) were identified from the Scottish Arthroplasty
Camilo Restrepo, MD, Philadelphia, PA Project (SAP) along with patients who had recorded DVT or
David Casper, MD, Philadelphia, PA PE events (Scottish Morbidity Database), varicose veins, and
varicose vein interventions. Statistical analysis was conducted
Ibrahim Raphael, MD, Philadelphia, PA
to determine a significant correlation between varicose
Matthew Austin, MD, Philadelphia, PA vein surgery and resulting DVT or PE post THA or TKA.
Javad Parvizi, MD, Philadelphia, PA RESULTS: Of the patient cohort that underwent THA, 462 (0.8%)
INTRODUCTION: Venous thromboembolism (VTE) is a had a diagnosed DVT within 90 days of orthopedic intervention.
common complication following total joint arthroplasty, ranging The DVT rate in patients who had previous VV surgery was 0.8%
from the frequently benign deep vein thrombosis (DVT) to the (27), and in those with no previous VV diagnosis or surgery was
distressing and at times fatal pulmonary embolism (PE). The aim 0.8% (428). In patients with a previous VV diagnosis but no VV
for prophylactic treatment of VTE is prevention of PE. However, surgery, the DVT rate was 3.1% (7) (Pearson Chi square test 14.8,
it has often been assumed that DVT is a proxy for PE. Based df 2, p=0.001). In the TKA cohort, 304 (0.6%) patients had a 90-
on this assumption, aggressive DVT prophylaxis is currently day DVT diagnoses. The DVT rate in patients who had previous VV
recommended at the expense of a higher proportion of bleeding surgery was 0.6% (22), and in those with no previous VV diagnosis
complications. This study investigates whether inferior vena cava or surgery was 0.6% (281). In patients with a previous VV diagnosis
(IVC) filter protects against PE. METHODS AND MATERIALS: We but no VV surgery, the DVT rate was 0.4% (1), a difference that did
identified 209 patients that underwent orthopaedic procedures not reach significance (Pearson Chi square test 0.1, df 2, p=0.95).
at a single institution with concurrent IVC filter placement Of the patient cohort that underwent THA, 403 (0.7%) had a
between 2004 and 2008. Fifty-one of these patients had an IVC diagnosed PE within 90 days of surgery. The PE rate in patients
filter placed following diagnosis of DVT to prevent “migration” who had previous VV surgery was 0.7% (26), and in those with no
of thrombus to the lungs and formation of PE. These patients previous VV diagnosis or surgery was 0.7% (376). In patients with
had an average age of 71.5 years and 30 (59%) were female. previous VV diagnosis but no VV surgery that PE rate was 0.4%
These patients were investigated for presence of DVT and PE. (1), a difference that did not reach statistical significance (Pearson
RESULTS: Two patients (3.9%) receiving IVC filter developed Chi square test 0.3, df2, p=0.85). In patients who had TKA, 411
PE after placement of the filter. There were no fatal PE in this (0.8%) had 90-day PE diagnoses. The PE rate in patients who had
cohort. One of these patients had concomitant atrial fibrillation. previous VV surgery was 0.9% (35), and in those who did not have
CONCLUSION This study identifies a high rate of PE despite IVC a VV diagnosis was 0.8% (374). In patients with a VV diagnosis
filter placement. This finding, once again, brings to question the but no surgery the PE rate was 0.9% (2), a difference that did not
“propagation theory” that assumes that PE arises from a thrombus reach significance (Pearson Chi square test 0.8, df 2, p=0.66).
in the extremity. Considering the fact that IVC filter has been shown CONCLUSION: DVT and PE is a major contributor worldwide to
to be very effective in prevention of migration of thrombus, our morbidity and mortality with one of the highest risk factors being
study demonstrates that a portion of PE may arise independently knee and hip surgery. Our study concluded that DVT and PE are
and as part of a hypercoagulable state. Thus, strategies that are major contributors worldwide to morbidity and mortality, with one
aimed at reducing DVT, by assuming DVT is a proxy for PE, needs of the highest risk factors being lower limb arthroplasty. Untreated
to be reexamined. We believe patients are placed at high risk of varicose veins are associated with an increased risk of DVT after
bleeding with administration of aggressive anticoagulation for hip arthroplasty, and it may be that patients with varicose veins
treatment of DVT and attempts to prevent its “propagation.” presenting for hip arthroplasty should consider treatment of
varicose veins prior to undergoing orthopaedic intervention. This
PAPER NO. 32 is the largest series of its kind reported to date. Further research
Is Previous Varicose Vein Surgery Associated with detailing relationships between known risk factors and the
decreased risk of DVT or PE post risk factor alleviation need to
Deep Vein Thrombosis within 90 Days of Hip and Knee be conducted in order to ascertain the best DVT/PE preventative
Replacement? approach.
Anahita Dua, MD, Brookfield, WI
Santiago S. Nieva, Edinburgh, United Kingdom
Alasdair G. Sutherland, MD, FRCS, Warrnambool, Australia
INTRODUCTION: Although varicose veins are an established risk
factor for deep vein thrombosis (DVT) there is a paucity of literature
detailing the association between prior varicose vein surgery and
DVT or pulmonary embolism (PE) in high-risk populations such
as patients undergoing knee or hip arthroplasty. The objective of
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
521 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
522 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
523 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
524 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
525 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
526 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
527 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
528 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
529 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
530 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
531 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
532 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
533 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
534 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
535 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
536 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
537 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
538 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
539 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
540 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
541 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
542 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
543 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
544 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
545 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
546 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
547 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
548 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
549 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
550 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
551 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
552 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
553 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
554 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
555 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
556 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
557 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
558 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
559 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
560 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
561 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
562 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
563 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
564 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
565 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
566 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
567 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
568 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
569 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
570 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
571 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
572 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
573 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
574 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
575 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
576 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
577 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
578 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
579 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
580 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
581 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
582 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
583 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
584 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
585 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
586 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
587 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
588 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
589 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
590 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
591 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
592 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
593 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
594 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
595 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
596 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
597 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
598 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
599 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
600 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
601 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
602 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
603 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
604 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
605 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
606 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
607 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
608 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
609 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
610 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
611 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
612 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
613 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
614 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
615 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
616 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
617 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
618 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
619 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
620 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
621 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
622 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
623 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
624 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
625 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.
u The FDA has not cleared the drug and/or medical device for the use described in this presentation (i.e. the drug or medical device is being discussed for an off label use).
626 For full information refer to page 14. An alphabetical faculty financial disclosure list can be found starting on page 19.